secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001193125-25-045605
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience closes $100M PIPE; stockholders approve divestiture of FYARRO business
--------------------------------------------------------------------------------

- Gross proceeds of $100M from PIPE led by Ally Bridge Group; 21.6M shares at $2.40 and 20.1M pre-funded warrants at $2.3999.
- Stockholders approved sale of FYARRO business to KAKEN INVESTMENTS INC. (16.6M for, 3.5M against).
- Equity plan amended to increase shares from 2.0M to 8.3M; annual reserve increase to 5% of outstanding.
- Proceeds from PIPE and FYARRO sale, plus existing cash, expected to fund operations into 2028.
- PIPE use includes upfront payments to WuXi Biologics and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312525045605/0001193125-25-045605-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312525045605/d892218d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-045605

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer